This is a prospective, multicenter screening cohort study designed to evaluate the feasibility of a blood-based multi-cancer early detection (MCED) test in an asymptomatic screening population. Eligible participants will undergo blood-based MCED testing, standard cancer screening as appropriate, and 1-year active follow-up. Participants with positive MCED results or highly suspicious findings from standard screening will undergo diagnostic evaluation to determine cancer status, enabling a more accurate assessment of the test's clinical performance.
This study consists of four stages: recruitment and enrollment, testing and screening, diagnostic evaluation, and follow-up. Approximately 1,250 participants will be recruited through community-based recruitment and invitations from family physicians to enhance the representativeness of the screening population. Peripheral blood will be collected from each participant for blood-based multi-cancer early detection (MCED) testing, which is designed to detect signals associated with five cancer types, including lung, colorectal, liver, gastric, and esophageal cancers. Participants will also undergo usual care and standard single-cancer screening, as appropriate, based on their individual cancer risk assessment. During the diagnostic stage, participants with positive MCED results will undergo diagnostic evaluation guided by the cancer site indicated by the MCED test. Participants with highly suspicious findings from standard screening or usual care will also undergo diagnostic evaluation according to applicable clinical guidelines. The number and types of diagnostic tests and procedures required to achieve diagnostic resolution will be recorded to assess the downstream diagnostic burden and safety of MCED. During the follow-up stage, cancer status will be actively followed. For participants diagnosed with cancer, relevant clinical information will be collected. In addition to the assessment of safety and performance, participant-reported outcome questionnaires will be administered at baseline, upon delivery of screening results, upon completion of the diagnostic evaluation, and at the 1-year follow-up to assess the psychological impact of MCED testing.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
1,250
A cfDNA methylation-based early cancer detection model that provides a binary positive/negative result and predicts the tissue of origin when a cancer-associated signal is detected.
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Huidong People's Hospital
Huizhou, Guangdong, China
Feasibility of MCED in the intended use setting
Descriptive statistics will be used to summarize the number of the five pre-specified cancers diagnosed by MCED.
Time frame: From enrollment to the Follow-up at 1 year
Safety of MCED in the intended use setting
Descriptive statistics will be used to summarize the time to diagnostic resolution following receipt of a positive MCED result and the number and types of diagnostic tests and procedures performed during the diagnostic evaluation.
Time frame: From enrollment to the Follow-up at 1 year
Performance of MCED in the intended use setting.
Positive Predictive Value defined as the proportion of participants confirmed to have the five target cancers among MCED positive individuals, compared against the clinical diagnostic gold standard. Negative Predictive Value defined as the proportion of participants free of the five target cancers among individuals with negative MCED test results, as compared with clinical diagnosis.
Time frame: From enrollment to the Follow-up at 1 year
Tissue-of-origin accuracy of MCED
Tissue-of-origin accuracy is defined as the proportion of participants with a correct tissue-of-origin prediction among those with a positive MCED test result and a confirmed cancer diagnosis.
Time frame: From enrollment to the Follow-up at 1 year
Participant-reported anxiety impact
Changes in anxiety over the course of the study will be assessed using the short form of the State-Trait Anxiety Inventory (STAI). The total STAI score and changes in the score across assessment time points will be summarized using descriptive statistics.
Time frame: From enrollment to the Follow-up at 1 year
Participant-reported health related quality of life (HRQoL)
Changes in HRQoL over the course of the study will be assessed using the EQ-5D-5L. The EQ-5D-5L utility value at each assessment time point and changes in the utility value over time will be summarized using descriptive statistics, with higher values indicating better health-related quality of life.
Time frame: From enrollment to the Follow-up at 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.